# Beamion LUNG-3 (NCT07195695)

> Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

No report yet. It can be ordered.

- Drugs tested: zongertinib
- Indication: resected stage II-IIIB NSCLC harboring HER2 TKD mutations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07195695
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Non-small Cell Lung Cancer
- Interventions: Zongertinib; Pembrolizumab; Atezolizumab; Durvalumab; Nivolumab
- Enrollment: 400
- Primary outcome: Disease-free survival (DFS) by investigator's assessment

## Indexed commentary on Beamion LUNG-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=beamion-lung-3-nct07195695